These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31622218)

  • 1. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
    Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
    Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
    Gupta S; Nag S; Aggarwal S; Rauthan A; Warrier N
    J Ovarian Res; 2019 Nov; 12(1):103. PubMed ID: 31685032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
    Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
    Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
    Freimund AE; Beach JA; Christie EL; Bowtell DDL
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.
    Mehrotra M; Phadte P; Shenoy P; Chakraborty S; Gupta S; Ray P
    Adv Exp Med Biol; 2024; 1452():65-96. PubMed ID: 38805125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
    Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
    Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype specific biomarkers associated with chemoresistance in epithelial ovarian cancer.
    Deo A; Mukherjee S; Rekhi B; Ray P
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S64-S69. PubMed ID: 32108633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
    Nag S; Aggarwal S; Rauthan A; Warrier N
    J Ovarian Res; 2022 Jul; 15(1):88. PubMed ID: 35902911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
    Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
    Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.